Fibrates, a class of hypolipidemic drugs able to activate peroxisome proliferator-activated receptor α (PPARα), were proven to be an effective treatment for patients with obesity, hyperlipidemia, and NAFLD. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.